NYSE:ABBVBiotechs
Assessing AbbVie (ABBV) Valuation After Fresh Regulatory Wins In Migraine And Blood Cancer
AbbVie (ABBV) stock has been in focus after a series of recent drug approvals, including European clearance for Aquipta in acute migraine, an expanded EU label for Venclyxto in first-line CLL, and FDA approval of Decnupaz for BPDCN.
See our latest analysis for AbbVie.
Those approvals have arrived alongside firm share price momentum, with AbbVie’s 1 month share price return of 10.83% and 7 day share price return of 4.37% standing against a slightly weaker 90 day share price return and strong 5...